Trial Profile
Safety Follow-up Through 180 Days of Treatment With Remestemcel-L in Study MSB-GVHD001 in Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Nov 2022
Price :
$35
*
At a glance
- Drugs Remestemcel-L (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Mesoblast
- 22 Nov 2022 According to a Mesoblast media release, the study is performed by the Center for International Blood and Marrow Transplant Research (CIBMTR).
- 21 Oct 2018 Status changed from recruiting to completed.
- 03 Apr 2018 Planned End Date changed from 1 Sep 2017 to 1 Jul 2018.